secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2023-11-27T23:59:59+00:00
Accession:  0001558370-23-019328
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus sets LOQTORZI price at $8,892.03/vial for NPC treatment
---------------------------------------------------------------

- FDA approved LOQTORZI (toripalimab-tpzi) on Oct 27 for first-line and later-line metastatic NPC.
- Coherus announced wholesale acquisition cost of $8,892.03 per single-use vial on Nov 27.
- LOQTORZI is co-administered with cisplatin and gemcitabine in first-line setting.
- This pricing establishes commercial launch basis for the PD-1 inhibitor in NPC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837023019328/0001558370-23-019328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837023019328/chrs-20231127x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer